FDA classifies Alzheimer's test for easier patient access
Published Date: 4/22/2026
Rule
Summary
The FDA is officially putting the Alzheimer's Disease Pathology Assessment Test into Class II, meaning it now has special safety rules but fewer red tape hurdles. This change helps make the test safer and easier to get to patients, starting April 22, 2026, with the classification retroactive to May 4, 2022. Doctors, patients, and device makers will benefit from faster access to this important tool without extra costs or delays.
Analyzed Economic Effects
4 provisions identified: 3 benefits, 1 costs, 0 mixed.
Alzheimer's Test Reclassified to Class II
The FDA has classified the Alzheimer’s disease pathology assessment test as Class II (special controls), effective April 22, 2026, with the classification applicable retroactively to May 4, 2022. This means the test is subject to special safety rules but is in a lower device class than automatic Class III, which the FDA says will reduce regulatory burdens and enhance patient access.
Makes Future Devices Easier to Market
Because FDA classified this test via the De Novo process, this device can serve as a predicate for future devices, allowing other device sponsors to use the less burdensome 510(k) process rather than repeat De Novo or premarket approval steps. If you make or plan to make similar diagnostics, this should reduce regulatory time and burden for follow-on products.
This Test Still Requires a 510(k) Submission
The FDA states that Alzheimer's disease pathology assessment tests remain subject to premarket notification requirements under section 510(k) because FDA has not determined that the device type should be exempt under section 510(m). If you manufacture this test, you must submit a 510(k) to reasonably assure safety and effectiveness.
New Safety, Performance, and Labeling Requirements
The final order establishes special controls requiring detailed design verification and validation (e.g., precision, linearity, assay interference, cross-reactivity, detection capability, specimen and reagent stability, and hook effect), clinical performance studies documenting APOE status and PET tracer usage, and labeling that must state the test is not a stand-alone diagnostic and cannot predict dementia or monitor therapy. If you use or interpret this test, these controls aim to improve result accuracy and how results are communicated.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-20727, Medical Devices; Immunology and Microbiology Devices; Classification of the System for Detection of Nucleic Acid From Non-Viral Microorganism(s) Causing Sexually Transmitted Infections Using Home-Collected Specimens
The FDA is officially classifying home test kits that detect non-viral germs causing sexually transmitted infections as Class II devices, meaning they have special safety rules but fewer hurdles than the strictest category. This change, effective October 9, 2026, helps make these tests safer and easier to get, benefiting patients and innovators alike. If you make or use these home test kits, this update means better access and clear safety standards without extra costs or delays.
Previous / Next Documents
Previous: 2026-07808, Airworthiness Directives; The Boeing Company Airplanes
The FAA just rolled out a new safety rule for Boeing 747-400 planes with certain upgrades. They found a problem where oxygen hoses could get damaged and cause sparks near cargo wiring, so now airlines must inspect and fix these parts by May 7, 2026. This keeps crews safe and avoids costly repairs later, with feedback open until June 8, 2026.
Next: 2026-07861, Medical Devices; Ophthalmic Devices; Classification of the Digital Therapy Device for Amblyopia
The FDA is officially classifying the digital therapy device for amblyopia (lazy eye) as a Class II device, meaning it has special safety rules but fewer hurdles than the strictest category. This change helps patients get access to this cool, innovative treatment faster and safer. The new classification is effective April 22, 2026, but it’s been in effect since October 20, 2021, so manufacturers can plan ahead without surprise costs or delays.